Group 1 - The core viewpoint of the article highlights the upcoming clinical use of a domestically developed fetal magnetocardiography device in Shanghai, which provides new evidence for early screening of complex congenital heart diseases, filling a technological gap in the domestic market [1] - The fetal magnetocardiography device is capable of non-invasive and contactless precise capture of fetal heart signals that traditional devices struggle to identify, representing a significant breakthrough in fetal heart health assessment [3] Group 2 - This innovative achievement has realized a complete innovation chain from technology research and development to industrial transformation, benefiting from the interdisciplinary medical-engineering collaboration established over the past twenty years between Shanghai Jiao Tong University and Shanghai Second Medical University [4] - The universities have implemented an "医+X" innovation model that breaks down traditional disciplinary barriers and supports the cultivation of interdisciplinary talents, alongside establishing a medical-engineering cross-research fund with a cumulative investment of approximately 674 million yuan, providing project funding to multiple medical fields [4]

Core Viewpoint - The article highlights the approval of the fetal magnetocardiography (fMCG) device by Mandi Medical, marking a significant advancement in non-invasive fetal cardiac monitoring technology in China, addressing a critical clinical need for early detection of fetal heart conditions [1][3][10]. Group 1: Product Approval and Technology - Mandi Medical's fMCG device is the first of its kind in China to be approved for collecting and recording fetal heart magnetic signals, representing a breakthrough in non-invasive fetal electrophysiological monitoring technology [1][3]. - The fMCG technology utilizes superconducting quantum interference device (SQUID) technology, which operates in a liquid helium environment to achieve high sensitivity, crucial for detecting the weaker fetal heart magnetic signals [6][10]. - The device is designed to be non-contact and radiation-free, ensuring no energy input or stimulation to the mother or fetus during monitoring [8]. Group 2: Clinical Need and Market Potential - Approximately 900,000 new cases of birth defects occur annually in China, with congenital heart disease (CHD) being a leading cause of non-accidental infant mortality, highlighting the urgent need for effective fetal heart monitoring solutions [3][10]. - The fMCG device is expected to significantly improve the diagnosis of complex arrhythmias and has been recommended by the American Heart Association for its unique value in fetal arrhythmia diagnosis and intrauterine medication guidance [9][10]. - The market for heart magnetocardiography devices in China is projected to grow from approximately 900 million yuan in 2024 to 23.4 billion yuan by 2027, with a compound annual growth rate exceeding 200% [10]. Group 3: Company Background and Future Directions - Mandi Medical, established in 2009, focuses on the research and commercialization of bio-magnetic medical imaging devices and has developed a multi-product line including adult and fetal heart magnetocardiography [11]. - The company collaborates with leading medical institutions for clinical research and aims to expand the indications for fMCG, including fetal electrophysiological abnormalities and preterm risk prediction [11][12]. - Future developments may integrate AI algorithms and remote collaboration systems, positioning fMCG as a key component in regional obstetric networks [12].